Patent ID: 11918651
Assignee: VISTERRA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 8:
9. A formulation comprising 25 mg/mL of an anti-dengue antibody molecule, 25 mM histidine, 50 mM to 150 mM sodium chloride, 75 mM arginine and/or 100 mM sucrose, and polysorbate 80 at a concentration of 0.02% w/v; wherein the formulation has a pH of 6 to 7, wherein the antibody molecule comprises:
(a) a heavy chain (HC) immunoglobulin variable region segment comprising:
an HC CDR1 comprising the sequence DVYMS (SEQ ID NO: 3),
an HC CDR2 comprising the sequence RIDPENGDTKYDPKLQG (SEQ ID NO: 4), and
an HC CDR3 comprising the sequence GWEGFAY (SEQ ID NO: 5),
as numbered according to the Kabat numbering system; and
(b) a light chain (LC) immunoglobulin variable region segment comprising:
an LC CDR1 comprising the sequence RASENVDKYGNSFMH (SEQ ID NO: 6),
an LC CDR2 comprising the sequence RASELQW (SEQ ID NO: 7), and
an LC CDR3 comprising the sequence QRSNEVPWT (SEQ ID NO: 8),
as numbered according to the Kabat numbering system, and
wherein 97% or more of the antibody molecules in the formulation are present as monomers.